Archive for the ‘Hypogonadism’ Category

The report provides a basic overview of the Androgen Replacement Therapy industry including its definition, applications and manufacturing technology.with leading business players.

Androgen replacement therapy, often referred to as testosterone replacement therapy, is a form of hormone therapy in which androgens, often testosterone, are replaced. ART is often prescribed to counter the effects of male hypogonadism. Rising aging male population with disease and increasing awareness about disease and therapy benefits dominating the market.

Augmented demand for the global Androgen Replacement Therapy market has been increased in the last few years. This informative research report has been scrutinized by using primary and secondary research.

Get a Sample Copy of Global Androgen Replacement Therapy Market Report @ https://inforgrowth.com/sample-request/4914309/androgen-replacement-therapy-market

Top Key Players: AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals

The Global Androgen Replacement Therapy Market Report represents highly detailed data including recent trends, Market demands, supply and distribution chain management strategies which will help to identify the workflow of Global Androgen Replacement Therapy Market Industry.

Global Androgen Replacement Therapy Market Report provides critical and detailed data for investment plans with research and development budgets, raw material budgets, labor cost, and other funds. Global Androgen Replacement Therapy Market industry is large enough to build a sustainable business, so this report helps you to identify the opportunities in Global Androgen Replacement Therapy Market by region: North America, Europe, Asia-Pacific, North America and Middle East and Africa.

Any Other Query, Ask Our Experts @ https://inforgrowth.com/report/4914309/androgen-replacement-therapy-market#speakAnalyst

Androgen Replacement Therapy Market by Type: Gels, Injections, Patches, Others

Androgen Replacement Therapy Market by Application: Hospitals, Clinics, Others

Major highlights of the global research report:

Finally, the researchers throw light on the different dynamics of the market such as drivers, restraints, and opportunities. Additionally, it offers exhaustive information about new products, developments, and investment.

Key Content of Chapters

1:Market Overview, Development, and Segment by Type, Application and Region2:Company information, Sales, Cost, Margin etc.3:Global Market by company, Type, Application and Geography4:Asia-Pacific Market by Type, Application and Geography5:Europe Market by Type, Application and Geography6:North America Market by Type, Application and Geography7:South America Market by Type, Application and Geography8:Middle East and Africa Market by Type, Application and Geography9:Market Features10:Investment Opportunity11:Conclusion

If you have any special requirements, please let us know and we will offer you the report as you want.https://inforgrowth.com/customization/4914309/androgen-replacement-therapy-market

About InForGrowth:

We are a market-intelligence company formed with the objective of providing clients access to the most relevant and accurate research content for their growth needs. At InForGrowth, we understand Research requirements and help a client in taking informed business critical decisions. Given the complexities and interdependencies of market-intelligence, there is always more than one source to explore and arrive at the right answer. Through our smart search feature and our reliable andamp; trusted publishing partners, we are paving way for a more simplified and relevant research.

For all your Research needs, reach out to us at:

Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USA

Contact Person: Rohan

Email:[emailprotected]

Phone: +1-909-329-2808

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Androgen Replacement Therapy Industry Analysis, Business Opportunities and Future Forecast 2024 by Top Key Players

Original post:
Androgen Replacement Therapy Industry Analysis, Business Opportunities and Future Forecast 2024 by Top Key Players - Infonews Box

Introduction

Mereo BioPharma (MREO) is a British small-cap ($62M) biopharma developing therapeutics for rare disorders as well as endocrine and oncological diseases. MREO has a diverse pipeline including MPH-966 (alvelestat), BCT-197 (acumapimod), and OMP-305B83 (navicixizumab) for alpha-1 antitrypsin deficiency, chronic obstructive pulmonary disease, and ovarian cancer, respectively. The focus of this article is BGS-649 (leflutrozole), a drug asset licensed from Novartis (NVS) that is in clinical development for treating hypogonadotropic hypogonadism (Hypo-H).

Hypogonadism is a medical condition characterized by a deficiency in testosterone, the primary male circulating sex hormone synthesized in the gonads. Hypogonadism can present itself during fetal development, before puberty or during adulthood. Testosterone is important in the development and maturation of reproductive tissues. Symptomatic events of this disorder are decreased libido, impaired erectile function, muscle weakness, increased adiposity, depressed mood, and decreased vitality.

Hypogonadism can be triggered by a primary testicular disorder (hypergonadotropic; Hyper-H) whereas hypogonadotropic hypogonadism (Hypo-H) is a consequence of congenital or acquired diseases that affect the hypothalamus and/or the pituitary gland.

The hypothalamus (i.e. brain), pituitary (i.e. endocrine), and gonadal (i.e. reproductive) glands are all often known as hypothalamic-pituitary-gonadal axis because they all act in concert in the development and regulation of the reproductive and immune systems. Any alteration in this axis induces changes in the hormones produced by each gland that can affect their various local and systemic effects on the body. Hypo-H is frequently reported in metabolic disorders such as obesity, type 2 diabetes, and metabolic syndrome.

Men who present with Hyper-H do not respond to hormone replacement medication because the disorder is caused by primary testicular failure. Testosterone hormone replacement is the mainstay treatment for Hypo-H to normalize testosterone levels and restore fertility. Alternative options include gonadotropin therapy regimen to induce endogenous testosterone, aromatase inhibitors, and selective estrogen receptor modulators.

BGS-649 (leflutrozole) is a novel once-weekly oral aromatase inhibitor in clinical development as first-line therapy for the treatment of Hypo-H in obese men. The thesis is that BGS-649 normalizes testosterone levels by inhibiting aromatase and is, therefore, expected to improve the related conditions. The premise is that lower levels of testosterone in obese men with Hypo-H is driven by high levels of the aromatase enzyme in fat tissue which irreversibly converts testosterone into estradiol. Aromatase inhibitors are widely used therapeutically in breast cancer.

Clinical Data: A Phase 2b clinical trial of BGS-649 in 271 patients with Hypo-H achieved its primary clinical endpoint of total testosterone normalization:

in over 75% of subjects after 24 weeks of treatment, and in at least 90% of patients after 24 weeks at the two highest doses. All three doses met all secondary endpoints, including the improvement of testosterone luteinizing hormone (LH.) and follicle stimulating hormone (FSH.) levels. The exploratory endpoint of improvement in total motile sperm count was also met.

A safety extension study completed in 143 patients successfully demonstrated that none of the doses of BGS-649 met the lower bound (95% confidence interval) of the pre-specified safety criterion of a greater than 3% reduction in lumbar spine bone mineral density (BMD) after 48 weeks of treatment. The extension study also demonstrated normalization of testosterone in more than 90% of the patients at all three doses and maintenance of the effects on LH and FSH.

Individuals with Hypo-H lack or have low levels of gonadotropin-releasing hormone (GnRH.). GnRH is a peptide hormone secreted from the hypothalamus and stimulates gonadotropic cells in the anterior pituitary gland to release LH and FSH for normal gonad function including testosterone production by the testes. The observation that BGS-649 therapy was associated with normal FSH and LH levels in the Phase 2b study could suggest these patients also had GnRH levels normalized or elevated.

The prevalence of Hypo-H was estimated to be 1:10,000 to 1:86,000 individuals 20 years ago - meaning the prevalence could be higher due to increasing rates of obesity.

Upcoming catalytic events are:

Setrusumab for Osteogenesis Imperfecta (OI.)

12-month data from Phase 2b ASTEROID study in adult OI patients expected in Q4 2019. In May 2019, Mereo reported positive 6-month interim data from the fully-enrolled ASTEROID study. These data were accepted for a late-breaking oral presentation at the upcoming American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting to be held from September 20-23 in Orlando, FL, USA. The Company expects to report 12-month topline data from the blinded portion of the study in Q4 2019. There are currently no FDA or EMA-approved treatments for OI.

Pivotal pediatric study ready in the EU and Canada. In addition to evaluating setrusumab in adult OI patients, Mereo's Paediatric Investigation Plan (PIP) has been approved by the EMA and a study design has been agreed for a pivotal registration trial in children. Mereo is also exploring an extension of the planned pivotal study into the U.S.

Alvelestat for Severe Alpha-1 Antitrypsin Deficiency (AATD.)

Enrollment continuing for the Phase 2 proof-of-concept study in severe AATD patients with topline data expected in mid-2020. If the results are positive, Mereo intends to commence a pivotal trial in the EU and the U.S. in AATD as soon as possible thereafter.

Investigator-sponsored clinical studies underway in AATD and also in bronchiolitis obliterans syndrome (BOS) as a result of graft-versus-host disease (GvHD) in patients undergoing hematopoietic stem cell transplantation (HSCT). BOS is an orphan disease characterized by inflammatory obstruction of the lung's tiniest airways and is the primary cause of death in patients who receive lung transplants. Based on the preliminary clinical data to-date, Mereo intends to investigate the use of alvelestat to treat patients with BOS following a lung transplant.

Partnering Discussions Continue for Broad Portfolio of Clinical-Stage Programs

Leflutrozole for Hypogonadotropic Hypogonadism .. Following the positive Phase 2b and six-month extension data reported in 2018, earlier this year Mereo held an advisory board to consider the future development strategy for leflutrozole, with a focus on the positive effects on semen parameters. Mereo has decided that future product development will focus on male fertility.

Acumapimod for Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) is Phase 3-ready following a successful Type B End of Phase 2 meeting with the FDA and agreed outline for a pivotal Phase 3 clinical trial program. Recently, a positive Scientific Advice Working Party (SAWP.) also took place with the EMA.

Navicixizumab for Advanced Platinum-Resistant Ovarian Cancer. In July 2019, Mereo held a successful Type B End of Phase 1 meeting with the FDA regarding a potential pathway for accelerated approval for navicixizumab for the treatment of patients with advanced ovarian cancer. Mereo and the FDA discussed, and agreed in principle, an outline for the design of a Phase 2 clinical trial that could potentially support the accelerated approval of navicixizumab in patients with ovarian cancer (including peritoneal or fallopian tube cancer) who have become resistant to prior therapies.

Etigilimab for Advanced Solid Tumors. Etigilimab has completed a Phase 1a/b trial of etigilimab, administered as either a single-agent or in combination with nivolumab, in patients with advanced or metastatic solid tumors.

The biggest risk is the low cash reserve. As highlighted above, MREO is seeking partnership agreements for some of its clinical programs. Partnership agreements would provide the financial stability needed to advance its clinical pipeline.

At the end of Q2/2019, it reported cash, cash equivalents, and short-term investments of $45.06M (after conversion from pounds sterling). Institutional ownership currently stands at 1.88%, with 43 institutional holders accounting for 1,805,180 total shares. Analysts recommend a buy with an average price target of $7.20.

CEO Dr. Denise Scots-Knight on the future:

Our team remains focused on advancing discussions with potential partners to help us further realize the value of these assets and we look forward to updating you regarding these discussions in the future. In addition to the progress have highlighted regarding our development programs, we also continue the build out of our senior Management Team and board of directors to ensure that we have the necessary expertise and are well positioned as our programs continue to advance.

Thanks for reading. While I occasionally cover companies like this, my focus remains investment opportunities in liver therapeutics, specifically NASH and Cholestatic liver diseases, which are exclusive to members of my private investing community, Liver Therapy Forum Marketplace.

As a Ph.D. trained liver biomedical scientist & Scientific Consultant, I provide:

Novel mechanistic insights and "updating thesis" highlighting promising drug candidates.

Exclusive access to full-length in-depth research analytical articles, KOL interviews, newsletters/digests, and Q & A chat board.

Actionable events to minimize risks and grow your investments.

Knowledge and wisdom required to understand the diverse and complex NASH therapeutics landscape.

Sign-up today to grow your investments!

Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in MREO over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: As always, my articles are meant to facilitate your understanding. Readers are expected to form their own trading plan, do their own research and take responsibility for their own actions. Investing in common stock can result in partial or total loss of capital. Please implement due diligence and invest wisely.

Originally posted here:
Mereo BioPharma And Leflutrozole In Hypogonadotropic Hypogonadism - Seeking Alpha

Hypogonadism is defined as hormonal disorder in which the glands (gonads & ovaries) produce little or no hormones causing its deficiency in the body. Hypogonadism in males refers to deficiency of testosterone due to dysfunction of either of the testes. Female hypogonadism refers to deficiency of estrogen or progesterone due to reduced activity of the ovaries. Hypogonadism is classified into two types: primary hypogonadism (testicular failure) and central hypogonadism (hypothalamic-pituitary axis dysfunction). Other major causes of hypogonadism include autoimmune disorder, genetic disorder, severe infections, and liver and kidney diseases. Generally, hormone and imaging tests are used to diagnose hypogonadism.

According to the Boston University School of Medicine, around 4 million to 5 million men in the U.S. were affected with hypogonadism in 2003. The incidence of hypogonadism in men aged between 40 years and 69 years in the country is around 481,000 new cases per year. According to the European Male Aging Study, the prevalence of late onset hypogonadism in men aged between 40 and 79 was 2.1% in 2016. Studies suggest that hypogonadism in adult men is often underdiagnosed and undertreated and only 5%. According to the Urology Care Foundation, hypogonadism is a chronic condition which would require lifelong treatment. The treatment for hypogonadism depends on the cause and concern about fertility and includes treatment such as hormone replacement therapy or assisted reproduction.

Men with heart disease, HIV, COPD, or renal disease have high prevalence of hypogonadism. Factors such as rising prevalence of type 2 diabetes and obesity further increase the incidence of hypogonadism. Growth of the global hypogonadism treatment market is attributed to rise in geriatric population, increase in infertility, and improved diagnosis. However, growing concerns about the potential side effects, availability of generic drugs, and preference for other natural hormonal boosters and supplements are likely to hamper the growth of the hypogonadism treatment market. Increasing awareness, awaiting approvals for new generation drugs in pipeline, and technological advancements present significant opportunities in the hypogonadism treatment market.

The primary treatment option for hypogonadism is hormone replacement therapy. Based on product type, the market has been classified into testosterone replacement therapy, estrogen therapy, and progesterone therapy. Testosterone replacement therapy is the fastest growing segment as hypogonadism is more prevalent in men. The segment is expected to hold major share of the global market during the forecast period.

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/hypogonadism-treatment-market.html

In terms of mode of administration, the hypogonadism treatment market has been broadly classified into transdermal patch, topical gel, buccal tablets, implantable pellet, intramuscular injections, and oral tablets. Transdermal patch followed by topical gels are anticipated to be the fastest growing segments as these provide steady route of administration and are easily modifiable over a short period of time. The oral and buccal tablets segments are anticipated to experience sluggish growth during the forecast period due to high side effects and liver diseases.

Based on the distribution channel they are segmented into hospital pharmacies, retail pharmacies and others. The major market share for the hypogonadism treatment market is for the retail pharmacies segment and is anticipated to rule the market during the forecast period as continuous long term treatment is required for the hypogonadism patient.

In terms of region, the global hypogonadism treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest market for hypogonadism treatment, accounting for more than half of the market share due to the factors such as increased adoption of newer highly advanced products, rising awareness about hormonal disorder including various treatment options available, and advancing health care infrastructure. However, Asia Pacific is anticipated to be the fastest growing market during the forecast period due to increasing urbanization and rise in the patient population.

Key players in the global hypogonadism treatment market are Bayer AG, Abbott Laboratories, Inc., Merck Serono, Sanofi, Merck & Co., Inc., Actavis, Inc., AbbVie Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Endo International plc, Ferring Holding S.A., and Laboratoires Genevrier.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Request For Custom Research At https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=30392&source=atm

The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis

The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request for TOC of This Report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=30392&source=atm

See original here:
Hypogonadism Treatment Market to Witness an Outstanding Growth by 2017 2025 - Space Market Research

Patent Expiry Blow Dealt to TRT Market Could be Softened by Growing Prevalence of Hypogonadism

A wide range of testosterone replacement therapy (TRT) products containing different active ingredients have been made available by a large number of both global and local manufacturers. With various studies estimating the number of men affected by hypogonadism (testosterone deficiency) at 30% worldwide, the demand for TRT is poised to increase gradually in the years ahead. The condition primarily affects men aged between 40 and 79 years, making this demographic a key target segment for market players.

Obtain Report Details @https://www.transparencymarketresearch.com/testosterone-replacement-therapy.html

However, the market is currently at a crucial juncture with top performing products losing their patents in the next few years. This will no doubt cause a major dent in revenues of key market players. However, some of this impact could be reduced by the heightened demand for and awareness levels about the benefits of advanced TRT products. Many of these products are now being utilized in testosterone deficiency treatment are likely to support market growth during the forecast period.

TRT Creams and Gels Continue to See Strong Sales Worldwide but Injections Racing Ahead

For the purpose of this study, the global testosterone replacement therapy market has been segmented on the basis of product type into creams/gels, patches, injections, gums/buccal adhesives, implants and oral drug forms. Of these, the creams/gels segment led the global market, as overall sales were mainly impelled by key branded formulations such as AndroGel from AbbVie, Inc. Axiron from Eli Lilly and Company, and Fortesta, Testim, and Natesto from Endo Pharmaceuticals Inc.

Get Sample with Latest Research @https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1097

Ease of use and comparatively less side effects have been the winning characteristics of gels/cream TRT products. However, this segment is expected to lose its current hold on the market owing to patent expirations of branded formulations.

TMR expects the injections product segment to witness the fastest CAGR from 2016 to 2024. This will be possible mainly because consumers are now more open to using these low priced products a factor aided by the increasing availability of self-administered forms of these products globally.

On the basis of active ingredients, the TRT market is segmented into testosterone, methyl testosterone, testosterone undecanoate, and testosterone enanthate and testosterone cypionate. Of these, testosterone as an active ingredient dominated the global TRT market in 2015. However, other active ingredients are expected to cover much ground through the forecast period. The demand for ester forms of testosterone such as testosterone cypionate and testosterone undecanoate is projected to show a healthy rise. Testosterone undecanoate is expected to witness the fastest growth through the reports forecasting horizon from 2016 to 2024.

Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1097

North America Leads TRT Market but Scales Tipping in Favor of Asia Pacific

Of the five broad geographical segments of the global testosterone replacement therapy market, North America accounted for the largest share (84.7%) of the market and was followed by Europe In 2015. The other key segments are Europe, Asia Pacific, Middle East and Africa (MEA), and Latin America.

The demand for advanced TRT products was especially strong in the U.S. in 2015 as the country accounted for 95% of the North America TRT market in that year, TMR has observed. Asia Pacific will greatly benefit from higher healthcare investments being channeled into the region and is expected to witness the fastest CAGR in the TRT market during the forecast period. China and India are markets that companies in the TRT market cannot ignore. In South Korea and Japan, on the other hand, the sizeable geriatric population and strong positive sentiments will aid the consumption of TRT products. Brazil is the key TRT market in Latin America with the single largest share 2015.

The key players operating in the global testosterone replacement therapy market are AbbVie, Inc., Allergan plc, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International plc, Mylan N.V., Novartis AG, and Pfizer, Inc. The testosterone replacement therapy market is somewhat consolidated with presence of a few large global players and some local vendors that are operating in the international market.

View original post here:
Testosterone Replacement Therapy Market: Increase in Incidence of Testosterone Deficiency to Drive the Global Market - Online News Guru

A new study published at the Journal of Urology shows a significant improvement in sexual and urinary functions and in the quality of life of men with hypogonadism who undergo long-term testosterone replacement therapy.

Urinary Health

Testosterone is a steroid hormone involved in the regulation of sexual function, urinary tract health and metabolism, as well as other important functions. In most men, testosterone levels decrease slowly with age and cannot cause immediate serious symptoms. However, some people may experience many signs and symptoms, such as a clinical condition called testosterone deficiency (TD) or male hypogonadism, which is attributed to inadequate testosterone levels. As a result, they experience symptoms ranging from fatigue, erectile dysfunction, low energy, decreased mood, and increased risk of diabetes.

Scientists from the Boston University School of Medicine have worked with a group of urologists in Germany to investigate the effects of prolonged testosterone replacement therapy on urinary tract health, sexual function, and quality of life of men with diagnosed symptomatic testosterone deficits. The study included more than 650 men aged between 50 and 60, some with an unexplained testosterone deficiency and others with known genetic and autoimmune causes of hypogonadism.

Testosterone treatment in men would enlarge the prostate and aggravate symptoms of the lower urinary tract according to Dr. Abdulmaged Traish a professor of urology at BUSM.

However, he and Dr. Gheorghe Doros, professor of biostatistics at BUSPH, discovered that despite the increased size of the prostate in the testosterone therapy group, there were fewer urinary symptoms such as frequent urination, incomplete emptying of the bladder, weak urine flow and waking up at night.

In addition to these subjective improvements, scientists conducted objective tests that showed that men who were treated with testosterone emptied their bladders more completely. Finally, testosterone treatment also increased patient outcomes based on the evaluation of their sexual erection health and overall quality of life.

The results of this study are of great importance for men with symptomatic testosterone deficits. Traish emphasized the value of this treatment option and stated that testosterone therapy is well tolerated with progressive and continuous improvement of urinary and sexual function and overall quality of life.

Read this article:
Testosterone Therapy Can Improve Urinary and Sexual Function in Men with Low T - Gilmore Health News

Hate group leaderMichelle Cretella of American College of Pediatricians dispenses medical advice based on Church dogma, not medical science.

via YouTube

The problem is: the thousands of people who die while taking these drugs are likely the terminally ill cancer patients who receive hormone blockers to fight hormone-sensitive cancers, like prostate cancer, according to experts.

Enter hate group leader Michelle Cretella (American College of Pediatricians)

She also pointed out that the FDA report shows that there were 11 deaths of children linked to this drug, none of whom were being treated for prostate cancer.

Without her knowledge, someone injected this crank with some sodium pentothol:

The use of Lupron to block puberty in children with gender dysphoria is not FDA approved in short because puberty is not a disease, she said.

In fact, giving puberty blockers to physically healthy children induces the disease known as hypogonadotrophic hypogonadism.

None of this blather has anything whatsoever to do with the wellbeing of children. The intent is to defend the teachings of the Catholic Church. At the risk of being repetitive, belief systems are based on faith. Medical science is based on evidence. The Church is out of bounds for attempting to conform the science to religious dogma.

Not treating pediatric gender dysphoria poses a significant risk of self-harm. Not treating pediatric gender dysphoria because of Catholic dogma is irresponsible and stunningly stupid. Any parent who follows Cretella's advice or the ramblings of LifeSiteNews is guilty of child abuse. Cretella's former professional society, the American Academy of Pediatrics, recommends gender-affirming care. That is based on exhaustive study.

Who are you going to listen to? A religious crank who has not practiced medicine in years (presumably to avoid continuing education obligations) or the professional associations whose only concern is the wellbeing of children?

Related content:

Read the original here:
Michelle Cretella whittles down "thousands of deaths" to 11 - The Slowly Boiled Frog

Anabolic steroids additionally called androgenic steroids are derivatives of testosterone, significant for advancing and keeping up muscle development and creating auxiliary male sex qualities, for example, an extending voice and facial hair. They are anabolic and increment protein inside cells, particularly in skeletal muscles, Anabolic steroids utilized restoratively in ailments to animate muscle increment, set off male adolescence and treat constant squandering conditions, comprising of malignancy and AIDS.

Increment in geriatric populace drives the androgens and anabolic steroids commercial center, as more men are susceptible to hypogonadism. Also, ascend in weight issues in men propels the overall androgens and anabolic steroids market. The growing negative health status specifically within the developing countries is projected to fuel the growth of the marketplace during the forecast period. Besides, rise in government ventures for higher human services is attributed to the growth of the overall androgens and anabolic steroids market. Increment in occurrence of hypogonadism among men is anticipated to enlarge the worldwide androgens and anabolic steroids market all through the forecast span. Rise in impotence among men due to weight problems and tiredness is expected to enhance demand for androgens and anabolic steroids during forecast duration.

Request for Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/29509

Anabolic Steroids Market can be segmented on basis of compound derivatives, mode of administration, applications, Distribution channels and geography.

On basis of synthetic derivatives, Anabolic steroids market is segmented as:

On basis of Modes of administration, Anabolic steroids is segmented as:

On basis of Applications, anabolic steroids is segmented as:

On basis of Distribution channels, anabolic steroids market is segmented as:

Anabolic steroids include di-hydro-testosterone, testosterone, and other marketers. Anabolic steroids stimulate the improvement of male sex organs and male sexual characters including growth of beard and deepening of voice. Various varieties of tissues grow due to stimulation of anabolic steroids, specifically muscle and bone. Rise in red blood cells production is due to anabolic results. Androgens and anabolic steroids are used for the remedy of breast cancer in ladies, impotence, hypogonadism in men, and alternative therapy delayed puberty in adolescent boys. Anabolic steroids are also used for the treatment of numerous conditions with hormonal imbalance, weight loss, osteoporosis, and anemia. Anabolic steroids market can be segmented based on synthetic derivatives, mode of administration, application, end-user, and region. In terms of mode of administration, the market can be categorized into oral, injection, topical, skin patches and inhaler. Based on application type, anabolic steroids market can be divided into Anabolic, Androgenic and others. Based on distribution channels anabolic steroids market can be classified into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment dominated the market owing to elevated availability of medications and hospitals being the first point of contact for treatment.

If you have any query, ask the analyst @ https://www.persistencemarketresearch.com/ask-an-expert/29509

Anabolic steroids market in North America held the biggest marketplace share due to expanded prevalence of breast cancer in women. According to many researches, breast cancers is one of the main cause of death in U.S. Europe held the second largest share in anabolic steroids market because of accelerated occurrence of hypogonadism in men and delayed puberty in adolescent boys. The Anabolic steroids market in Asia Pacific is expected to grow at a fast pace during the forecast period attributable to multiplied government initiatives to get rid of breast cancer. Anabolic steroids market in Middle East & Africa is predicted to be driven via improved occurrence of impotence, hypogonadism in men, and behind schedule puberty in adolescent boys. The market in Latin America is projected to witness robust increase at some point of the forecast length due to accelerated government tasks within the fitness care sector.

Valeant, Endo Pharmaceuticals Solutions Inc., Germiphene Corporation, Taro Pharmaceuticals, Inc., Antares Pharma, Inc, Actavis Pharma, Inc, Sandoz, Pfizer, Unimed Pharmaceuticals, Upsher-Smith and others

See original here:
Rapid Advancements in Anabolic Steroids Market to Fuel Revenues Through 2029 - Space Market Research

By Brandon Showalter, CP Reporter | Thursday, September 26, 2019 Lupron, puberty blocker and prostate cancer drug.

Drugs that are being used to halt puberty in gender-confused youth have been linked to thousands of adult deaths, government data show.

The Food & Drug Administration has recorded thousands of deaths associated with Lupron, a puberty-blocking drug that is routinely used to treat prostate cancer in men and endometriosis in women. Adverse complications related to its use include breast disorders, malignant neoplasms, and psychiatric and nervous disorders.

Lupron and other drugs in its class significantly alters the hormone levels in the body and has been documented to contribute to blood clots and other cardiovascular complications, as well as brittle bones and faulty joints.

Between 2004 and June 30 of this year, the FDA documented33,478 adverse reactionssuffered by patients who took Leuprolide Acetate (Lupron), which is used as a hormone blocker. More than 19,054 reactions were considered "serious," including 6,056 deaths.

The figure rises when factoring in the total number of adverse reactions logged by the FDA since 1984. In total, there have been 40,764 adverse reactions, 25,513 of those were considered "serious," among those were 6,370 deaths.

Lupron is being prescribed off-label for use in children who have been diagnosed with gender dysphoria despite the lack of formal FDA approval for that purpose. The drug is clinically approved for treatment of precocious puberty, a condition where children start their pubertal processes at an abnormally early age and the blocker is administered for a short time until the proper age.

"The first well-documented case report of a puberty blocker like Lupron (a similar medication called Triptorelin which has an identical mechanism of action) being used in a young patient with gender confusion was published out of Holland in 1998 where a pediatric endocrinologist, working together with a psychiatrist, decided to use the medication on a 13-year-old girl suffering from gender dysphoria,"Michael Laidlaw, a Rocklin, California-based endocrinologist, told The Christian Postin a previous interview.

Reports have emerged in recent years showing that the pediatric version of the drug comes with few warnings about long-term side effects and leads to lasting and severe health problems.

When injected into a physically healthy body, the drug interrupts a normally-functioning endocrine system, yielding hypogonadotropic hypogonadism, according to Laidlaw.

Its a serious condition that endocrinologists would normally diagnose and treat because it interferes with development, but in [gender dysphoria] cases theyre inducing this disease state, he said in aninterviewwith the National Catholic Register.

In 2017, the FDA said it was "conducting a specific review of nervous system and psychiatric events in association with the use of GnRH agonists, [a class of drugs] including Lupron, in pediatric patients, in response to questions from Kaiser Health News and Reveal from the Center for Investigative Reporting. The government agency was also reportedly reviewing seizures that stemmed from use of Lupron's pediatric version and other drugs in its class.

Transgender activists often promote such drugs as a "pause button" on life, giving young people additional time to decide whether to proceed to cross-sex hormones and surgical transition.

The therapeutic idea behind the use of Lupron for treatment of prostate cancer is that by inhibiting the flow of testosterone over the prostate and reducing it to a low, undetectable level, prostate cancer tissue is prevented from growing, Laidlaw told CPin a previousinterview about the drug's dangers.

Unlike prostate cancer, a disease where the drug at least serves the purpose of targeting the malignant masses on the organ, Laidlaw said he knows of no psychological condition that is treated by putting hormones out of alignment from their normal levels.

"Gender dysphoria is not an endocrine condition, but is a psychological one and should, therefore, be treated with proper psychological care. But it becomes an endocrine condition once you start using puberty blockers and giving cross-sex hormones to kids," Laidlaw stressed at the time.

According to the annual report of AbbVie, the company that produces Lupron, sales of the drug were approximately $669 million in 2017 in the United States alone.

England's lone gender clinic, the Tavistock Centre in London, has come under scrutiny in recent months in part because of intensifying public concern about puberty blockers.

Kirsty Entwistle, who until last October was a staff psychologist at the Gender Identity Development Service in Leeds, accused Tavistock clinicians in July of misleading young patients, saying they were making decisions that will have a major impact on children and young peoples bodies and lives ... without a robust evidence base" and said the facility had troubling internal practices.

Children and their families were being told that puberty-suppressing drugs used to transition youth were "fully reversible," when in fact the drugs' long-term effects remain unknown, she said, noting that an "unspoken rule" existed within the clinic that clinicians were never to inform families that their children were not transgender.

Visit link:
Drugs used as puberty blockers in youth linked to thousands of adult deaths, FDA shows - The Christian Post

AMA Research added a comprehensive research document of 200+ pages on Testosterone Replacement Therapy market with detailed insights on growth factors and strategies. The study segments key regions that includes North America, Europe, Asia-Pacific with country level break-up and provide volume* and value related cross segmented information by each country. Some of the important players from a wide list of coverage used under bottom-up approach are

Request a sample report @ https://www.advancemarketanalytics.com/sample-report/46424-global-testosterone-replacement-therapy-market

Testosterone is responsible for the development of male sexual characteristics and this hormone formed by the testicles. Insufficient production of testosterone causes erectile dysfunction. Testosterone Replacement Therapy (TRT) is generally termed as hormone therapy for men, designed to counteract the effects of reduced activity in the gonads or hypogonadism. Hypogonadism in men is clinical syndrome, which results in the failure of the testes to produce physiological levels of testosterone. Erectile dysfunction arises due to reduce testosterone production to overcome this testosterone replacement therapy is used to improve the problem.

Market Segmentation

by Type (Creams or Gels, Patches, Injections, Buccal Adhesives, Implants, Oral), Application (Hospitals, Clinics) Market Concentration Insights:

CR4, CR8 and HHI Index Analysis

Comparative Market Share Analysis (Y-o-Y)

Major Companies Market Position and Development Strategy

Emerging Players Heat Map Analysis

Check for Discount @ https://www.advancemarketanalytics.com/request-discount/46424-global-testosterone-replacement-therapy-market

Highlights of Influencing Trends: Increasing awareness about testosterone substitute therapy

Market Growth Drivers: Increasing prevalence of hypogonadism in adult men

The need for having an offspring amongst men

Restraints: High possibility of side effects related to testosterone replacement therapy

View Detailed Table of Content @ https://www.advancemarketanalytics.com/reports/46424-global-testosterone-replacement-therapy-market

Country level Break-up includes:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)

Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

On Special Request we do offer a dedicated and focus report on regional or by country level scope.

Get full copy of United States Testosterone Replacement Therapy Market Study @ USD 2000

And, Europe Testosterone Replacement Therapy Market Study @ USD 2500

Highlights from Table of Content (TOC):

1 Report Overview

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered

1.4 Market Analysis by Type

1.5 Market by Application

1.6 Study Objectives

1.7 Years Considered

2 Global Growth Trends

2.1 Global Testosterone Replacement Therapy Market Size

2.2 Testosterone Replacement Therapy Growth Trends by Regions

2.3 Industry Trends

3 Market Share by Key Players

3.1 Global Testosterone Replacement Therapy Market Size by Manufacturers

3.2 Global Testosterone Replacement Therapy Key Players Head office and Area Served

3.3 Key Players Product/Solution/Service

3.4 Enter barriers in Testosterone Replacement Therapy Market

3.5 Mergers, Acquisitions, Expansion Plans

4 Testosterone Replacement Therapy Market by Product

4.1 Global Testosterone Replacement Therapy Sales by Product

4.2 Global Testosterone Replacement Therapy Revenue by Product

4.3 Global Testosterone Replacement Therapy Price by Product

5 Testosterone Replacement Therapy Market by End User

5.1 Overview

5.2 Testosterone Replacement Therapy by End User

*Customized Section/Chapter wise Reports or Regional or Country wise Chapters are also available.

Buy this report @ https://www.advancemarketanalytics.com/buy-now?format=1&report=46424

Contact Us:

CRAIG FRANCIS (PR & Marketing Manager)

sales@advancemarketanalytics.com

Ph: +1 (206) 317 1218

More:
Testosterone Replacement Therapy Market: A Straight Overview of Growing Market & Future Trend by 2024 - Research Newscast

According to Persistence Market Researchs new report, globalmale hypogonadism marketis slated to exhibit a steady expansion throughout the forecast period (2017-2026). Revenues from the global market for male hypogonadism are estimated to exceed US$ 3,300 Mn by 2026-end.

Governments Taking Initiatives to Spread Awareness about Male Hypogonadism Therapeutics

Lack of sex hormones, usually referred to as male hypogonadism has resulted into many health risks that include osteoporosis, heart disease, and cardiovascular diseases on the back of thinning of bones. Global male hypogonadism market comprises several patented brands that currently have high market penetration. Proliferation in geriatric population in tandem with rising incidences related to rheumatoid arthritis and obesity have been primary factors affecting prevalence of male hypogonadism globally. Mounting incidences of testosterone deficiency in male population is a key factor that prevalence of male hypogonadism has surged worldwide. Several governments around the world have been taking initiatives to spread the awareness on hypogonadism treatment procedures, for example testosterone replacement therapy (TST), in order to relieve the painful burden on patients and their families.

As low testosterone levels are increasingly associated with exacerbation of chronic conditions, it further results into disorders apropos to hypothalamic-pituitary-gonadal axis. Advent of TST has however enabled reduction in cases of male hypogonadism considerably. With growing awareness related to its treatment among patients, the market is likely to gain an uptick during the forecast period. Rising availability of the selective androgen receptor modulators (SARMs) has further sustained the market expansion. The development and high availability of SARMs has led toward the provision of improved treatment procedure to patients having androgen deficiencies, thereby influencing the market growth.

Get Sample Copy Of This Report @https://www.persistencemarketresearch.com/samples/22303

North America will continue to Dominate Global Male Hypogonadism Market

North America will continue to dominate the global male hypogonadism market, with more than one-third revenue share during the forecast period. In addition, revenues from the male hypogonadism market in North America will exhibit the fastest expansion through 2026, as compared to those from all the other regional segments comprised in the report. Europe and Asia-Pacific excluding Japan (APEJ) are also expected to remain lucrative for the male hypogonadism market. The market in APEJ will ride on a slightly higher CAGR than that in Europe through 2026.

Topical gels are expected to remain the most lucrative among drugs available for treatment of male hypogonadism globally, with sales projected to register the fastest expansion through 2026. Injectables will also remain a major revenue contributor to the market. Sales of injectable and transdermal patches are poised to reflect an equal CAGR through 2026.

Testosterone Replacement Therapy to Remain Preferred among Patients

Based on therapy, testosterone replacement therapy is expected to remain preferred among patients with male hypogonadism worldwide. Roughly 66% revenue share of the market is expected to be held by revenues from testosterone replacement therapy by 2026-end. Revenues from gonadotropin replacement therapy will remain slightly more than half revenues gained from testosterone replacement therapy throughout the forecast period.

Klinefelters syndrome is expected to remain the most prevalent disease type observed in the male hypogonadism market, and revenues from treatment of this disease will exceed US$ 1,800 Mn by 2026-end. Kallmann Syndrome and Pituitary Adenomas among disease types will also account for major revenue shares of the market by 2026-end.

For More Information Ask An Expert @https://www.persistencemarketresearch.com/ask-an-expert/22303

Nature of global male hypogonadism market has been observed to be highly competitive. This can be mainly attributed to occupancy of many small as well as large suppliers. New companies entering the male hypogonadism market are leveraging opportunities related to treatment developments and innovations. Strategic alliances are likely to remain strong among vendors for producing and marketing drugs worldwide, thereby increasing their market reach. Active market players listed by PMRs report include Astrazeneca Plc., Merck & Co. Inc., Laboratories Genevrier, Bayer AG, Endo International Plc., Allergan Plc., Ferring, Finox Biotech, AbbVie Inc., Eli Lilly and Company Ltd., Teva Pharmaceutical Industries Ltd., and IBSA Institut Biochimque.

More here:
Male Hypogonadism Market estimated to exceed US$ 3300 Mn by 2026-end - Wolf Mirror

The prime objective of Global Male Hypogonadism Market 2019-2023 report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing.

Deep researches and analysis were done during the preparation of the Male Hypogonadism market report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Get Sample Copy of this report at https://www.abrreports.com/industry-insights/2019-2024-global-and-regional-male-hypogonadism-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report?form=request-report-sample

Lack of sex hormones, generally referred to male hypogonadism, results into several health risks such as osteoporosis and heart disease, owing to thinning of bones. The global market for male hypogonadism comprises several patented brands with high market penetration. Growth in geriatric population along with rising incidences of rheumatoid arthritis and obesity are primary factors influencing prevalence of male hypogonadism.

By Market Players:Endo International Plc, Eli Lilly and Company Ltd., AbbVie, Inc., Pfizer, Inc., Merck KGaA, Allergan Plc, Sun Pharmaceutical Industries Limited, Ferring B.V.

By TherapyTestosterone Replacement Therapy, Gonadotropin Replacement Therapy ,

By Drug TypeTopical Gels, Injectables, Transdermal Patches, Others ,

By Disease TypeKlinefelters Syndrome, Pituitary Adenomas, Kallmann Syndrome, Other Types

The points that are discussed within the report are the major market players that are involved in the market such as manufacturers, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. The historical data from 2012 to 2017 and forecast data from 2018 to 2023.

The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail. Data and information by manufacturer, by region, by type, by application and etc, and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Click to access full report and Table of Content at https://www.abrreports.com/industry-insights/2019-2024-global-and-regional-male-hypogonadism-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

Key pointers of the Table of Contents:

Chapter 1 Industry OverviewChapter 2 Production Market AnalysisChapter 3 Sales Market AnalysisChapter 4 Consumption Market AnalysisChapter 5 Production, Sales and Consumption Market Comparison AnalysisChapter 6 Major Manufacturers Production and Sales Market Comparison AnalysisChapter 7 Major Material AnalysisChapter 8 Major Type AnalysisChapter 9 Industry Chain AnalysisChapter 10 Global and Regional Market ForecastChapter 11 Major Manufacturers AnalysisChapter 12 New Project Investment Feasibility AnalysisChapter 13 ConclusionsChapter 14 Appendix

Key Reasons to Purchase

To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.Assess the production processes, major issues, and solutions to mitigate the development risk.To understand the most affecting driving and restraining forces in the market and its impact in the global market.Learn about the market strategies that are being adopted by leading respective organizations.To understand the future outlook and prospects for the market.Besides the standard structure reports, we also provide custom research according to specific requirements.

Purchase the report @

https://www.abrreports.com/industry-insights/2019-2024-global-and-regional-male-hypogonadism-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report/checkout?option=one

About Us:

ABR Reports (Advanced Business Research Reports) is the premium market research reselling company which offers market research reports to individuals, organizations and industries to enhance and strengthen the decision making process. With associate thoroughgoing list of market research Publishers we tend to cut across over all the business verticals covering 5000+ micro markets and offer market size and share analysis, industry trend, information on products, regional market and keen business insights to our clients.

Contact Us:

Scott HarrisSales ManagerEmail ID: [emailprotected]Phone No.: +1-561-448-7424

See original here:
Global Male Hypogonadism market 2019 Expected to Grow faster according to new research report - Commerce Gazette

Global Male Hypogonadism Market: Snapshot

Hypogonadism in males refers to a condition in the male body where the testes show a significantly reduced level of functioning than normal. The overall result of male hypogonadism is a reduction in the rate of biosynthesis of male sex hormones. This state is more commonly known as interrupted stage 1 puberty. Hypoandrogenism, or the low androgen or testosterone level in a male can vary in severity from person to person. It is often the cause of partial or complete infertility. There are multiple forms of male hypogonadism and even more ways to classify them. Most endocrinologists commonly classify male hypogonadism on the basis of the level of defectiveness of the male reproductive system.

Get Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1127

In many cases, doctors also measure the level of gonadotropins to classify a patient between primary and secondary male hypogonadism. Primary male hypogonadism refers to the cause of the condition being due to defective gonads. There are different types of primary male hypogonadism, including Turner syndrome and Klinefelter syndrome. Secondary male hypogonadism is caused by defects in pituitary or hypothalamic glands. They include Kallmann syndrome and hypopituitarism.

Global Male Hypogonadism Market: Overview

Male Hypogonadism refers to a clinical condition, wherein the testes fail to produce enough testosterone leading to delayed puberty or incomplete development. The condition is related to impaired development of muscle mass, development of breast tissues, impaired body hair growth, and lack of deepening of the voice.

The male Hypogonadism market can be segmented by therapy, type, drug delivery, and geography.

The report presents an in-depth analysis of the global male hypogonadism market with current trends and future estimates to explain the imminent investment pockets. The quantitative analysis of the market for the forecast period from 2017 to 2025 will enable stakeholders to capitalize on the prevailing growth opportunities.

Global Male Hypogonadism Market: Trends and Opportunities

The top driver of the male hypogonadism market includes rising prevalence of testosterone deficiency among men, increasing infertility rates, and increasing awareness among individuals about hypogonadism treatment due to awareness drives organized by several governments across the world. Moreover, high risk of hypogonadism among the geriatric population with obesity and diabetes, and increasing prevalence of chronic disorders among the geriatrics are further expected to boost the markets growth.

However, factors such as high side effects of testosterone products are challenging the growth of testosterone replacement therapy market. Top players in the market are focused on research and development to introduce newer products with fewer or negligible side effects and improved results. For example, LPCN 1111, a product which is under development from Lipocine Inc., is a newer testosterone prodrug that utilizes Lipral technology for enhanced systemic absorption and for enhanced solubility of testosterone. Nevertheless, technological advancements are anticipated to extend new opportunities to the markets growth.

Request TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1127

Global Male Hypogonadism Market: Regional Overview

The global male Hypogonadism market can be analyzed with respect to the regional segments of North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. North America held the majority share of the global market in the recent past and is expected to retain its dominant position in the near future. This is mainly due to the rise in the number of individuals suffering from primary and secondary conditions of hypogonadism, and rising awareness among individuals about treatment options for the condition. Moreover, the presence of ultra-modern healthcare infrastructure and increasing popularity of technologically advanced products are expected to offer new opportunities for top players in this market. The region is closely followed by Europe.

Asia Pacific is expected to offer lucrative opportunities to this market due to the modernization of the healthcare infrastructure in the emerging economies of India and China and the increasing awareness about the treatment for the condition. In Asia Pacific, the increasing prevalence of hypogonadism and infertility rates along with the rising geriatric population base with diabetes and obesity are propelling the growth of this market. China, Taiwan, and Malaysia are some of the countries that display the highest rate of male hypogonadism.

Major Companies Mentioned in Report

Some of the key players in the male Hypogonadism market include AbbVie Inc., Astrazeneca plc, Eli Lilly and Company Ltd., Merck & Co. Inc., SA, Finox Biotech, Laboratories Genevrier, Teva Pharmaceutical Industries Ltd., Allergan plc, Bayer AG, Endo International plc, IBSA Institut Biochimque, and Ferring.

Key players are focused on product approval for growth considerations and to cater to the changing demand of the industry. The introduction of innovative and technologically advanced products is also the focus of key players to increase their market share and for serving patients in a better manner.

Get Discount on Latest Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1127

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

View post:
Male Hypogonadism Market Size(Value and Volume) by 2025 - ScoopJunction

Murfreesboro Medical Clinic & SurgiCenter is committed to meeting the needs of Rutherford County's growing community. In addition to adding two new locations in 2019, MMC will be adding five new doctors to its team of physicians.The physicians joining MMC this fall are: Christopher Albergo, M.D. (Endocrinology), Lauren Blackwell, D.O. (Pediatrics), C. Brad Bledsoe, M.D. (Dermatology), Britni Caplin, M.D. (ENT), and Brittany Cook, M.D. (Ophthalmology)."With a national shortage of physicians, it is becoming more and more challenging to find quality physicians to meet the growing healthcare needs of our community," noted Joey Peay, MMC's Chief Executive Officer. "For MMC to find five quality physicians to join us in 2019 in addition to the nine that began practicing at MMC in 2018 is truly remarkable! Each of them will be a valuable member of our medical team and a wonderful member of the Murfreesboro community."Christopher Albergo, M.D. is a board-certified Endocrinologist skilled in general endocrinology, including Hypothyroid, Parathyroid, Thyroid Cancer, Graves' Disease, Pituitary disorders, Adrenal disorders, Hypogonadism , PCOS, Obesity, Diabetes and Osteoporosis. Lauren Blackwell, D.O. is a board-certified Pediatrician skilled in general pediatrics, acute and chronic conditions, as well as routine check-ups and sports physicals for children birth through 18 years of age. Her special interests include ADHD and newborn care. She is also an advocate for breast feeding and enjoys working with moms and newborns to promote successful breast feeding.C. Brad Bledsoe, M.D. is a board-certified Dermatologist skilled in general and surgical dermatology, skin cancer detection, treatment and prevention, precancerous skin lesions (actinic keratoses) and sun damaged skin, acne, rosacea, psoriasis, eczema, dry skin, and other rashes, warts and other viral, bacterial and fungal skin infections, cysts, lipomas, and other nodules, laser procedures, teledermatology and medical technology. Britni Caplin, M.D. is a board-certified Otolaryngologist skilled in adult and pediatric Otolaryngology, Thyroid and Parathyroid Surgery, Otology, Nasal and Sinus Surgery including Balloon Sinuplasty and other In-Office Procedures, and Head and Neck Surgery.

Brittany N. Cook, M.D. is a board-certified Ophthalmologist skilled in Cataract surgery including Refractive Cataract surgery, Toric and Multifocal lens implants, Dry eyes, Blepharitis and Ocular Surface Disease, Refractive surgery including LASIK and PRK, Ocular surface growths including Pterygia, Macular degeneration, Diabetic retinopathy, and Glaucoma.

Read more here:
Murfreesboro Medical Clinic & SurgiCenter is proud to announce the addition of five new physicians to its practice in 2019 - Wgnsradio

Male hypogonadism is a condition in males wherein the testes depict a significantly reduced functioning level than normal. Reduction in rate of biosynthesis of the male sex hormones consequently results into male hypogonadism, which can vary in terms of severity among individuals. Partial or complete infertility are among major end-results entailing male hypogonadism, which in turn have created the need for effective treatment. XploreMR has published a new comprehensive research report titled, Male Hypogonadism Market: Global Industry Analysis (2012-2016) and Forecast (2017-2026). The report covers present market scenario as well as imparts future growth prospects of the male hypogonadism market for the period between 2017 and 2026. The report also engulfs key drivers, hindrances, opportunities and trends that are affecting expansion of the global male hypogonadism market. The report offers an overall picture of the global male hypogonadism market, in order to help businesses seeking opportunities for making investments in the market.

Get Sample Copy of this report at https://www.xploremr.com/connectus/sample/517

Structure of the Report

The report provides an exhaustive synopsis of the global male hypogonadism market, engulfing an executive summary that elucidates the core trends influencing the market expansion. This chapter also sheds light on impacts that the dynamics are likely to pose on growth of the market in the long run. The report also imparts figures appertaining to CAGRs from a historical and forecast point of view. An overview of the global male hypogonadism market follows the executive summary, and issues a clear picture of the markets scope to the report readers. The overview includes a concise market introduction succeeded by a formal definition of male hypogonadism. Chapters subsequent to the overview elaborates several dynamics including driving factors, limitations and prospects being observed in the market through the forecast period. Meanwhile these chapter also inundate detailed insights related to the bottom line of enterprises, global economy and fiscal stimulus.

Browse Full Report at https://www.xploremr.com/report/517/global-male-hypogonadism-market

Competition Landscape

This analytical research report on the global male hypogonadism market is a complete package, which includes intelligence on key participants underpinning the market expansion. In the last chapter of the report, which elucidates the competitive scenario of the market, strategies implemented by the market players, along with their product overview, company overview, key financials, key developments and SWOT analysis has been rendered exhaustively. In addition, region-wide spread of these market players, their future expansion plans, market shares, revenues, and mergers & acquisition activities between them have been described in detail in this concluding chapter of the report. An intensity map has been employed in the report to profile the market players situated across geographies.

Research Methodology

Credibility of the researched statistics and data is backed by the unique research methodology employed by the analysts at XMR, which ensures higher accuracy. XMRs research report on the global male hypogonadism market can assist its readers in gaining detailed insights on many different aspects governing the market around key regional segments included in the report. The report readers can further slate key strategies for tapping into vital revenue pockets and gaining benefits over the intensifying competition in the market. Information presented in the report has been scrutinized and monitored thoroughly by XMRs industry experts. Figures and numbers offered in the report have also been validated by the analysts in order to facilitate strategic decision making for the report readers.

Buy Full Report at https://www.xploremr.com/cart/517/SL

Read this article:
Male Hypogonadism Market To Increase at Steady Growth Rate - Herald Space

The global market for testosterone replacement therapy is characterized by the presence of a large number of small and large scale manufacturers. All of the manufacturers have been steadfast in filling the meagre market gap in order to enhance their prospects of growth. Furthermore, research and development has been the central characteristic of al the market players operating in the global market. In 2015, it was found that 80% of the total market share was held by the top five market vendors with AbbVie Inc. taking the lead.

The large scale vendors are focusing on establishing an iconic brand for their product by resorting to rigorous marketing and advertising tactics. The smaller companies are expected to concentrate on capturing the local and regional markets to sustain themselves in the current scenario of stiff competition. A negative implication for the leading market players in recent times has been the loss of patents for their products. This has not only plundered them of revenues but has also affected the workflow of these companies.

The market players are expected to launch awareness campaigns about testosterone replacement therapies in order to educate and inform the consumers. Hence, the market for testosterone replacement therapies is expected to witness the emergence of several new trends and opportunities over the forthcoming years. Some of the key players in the global testosterone replacement therapy market include Bayer AG, Endo Pharmaceuticals, Inc., Novartis AG, and Allergen plc.

The CAGR for theglobal testosterone replacement therapy marketis estimated to be -4.20% over the period between 2016 and 2024. The negative growth rate of the global market is expected to take the market value from US2.0 bn in 2015 to a decreased value of US$1.3 bn by 2024-end.

GetSample with Latest Research @https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1097

High Incidence of Hypogonadism to Drive Market Demand

Research studies suggest that around 30% of all men suffer from testosterone deficiency, which has driven demand within the global market for testosterone replacement therapy. Furthermore, the population demographic of men in the age range of 40-79 years is more likely to suffer from testosterone deficiency. The need for mutation or having an offspring amongst men in the aforementioned age range has driven demand within the global market.

Moreover, the geriatric population has been on a rise, which underhandedly contributes to market growth. Several campaigns aimed at educating people about the benefits of testosterone replacement therapy have been an important propeller of demand within the global market. It is anticipated that more people suffering from testosterone deficiency would resort to these therapies over the coming years.

Side Effects of Testosterone Replacement Therapy Could Obstruct Market Growth

Despite the rising awareness amongst the masses about the advantages of testosterone replacement therapies, the market growth is hindered by the apprehension of the people. The chances of developing metabolic disorders are higher in men who undergo testosterone replacement therapies. Furthermore, the risk of developing cardiovascular diseases also discourages people from resorting to testosterone replacement therapies. The FDA has also cautioned people about the use of such therapies by issuing strict warnings, which has further obstructed the growth of the global market.

See original here:
Testosterone Replacement Therapy Market : Analysis and Opportunity Assessment 2016-2024 - OnYourDesks

Hypogonadism is defined as hormonal disorder in which the glands (gonads & ovaries) produce little or no hormones causing its deficiency in the body. Hypogonadism in males refers to deficiency of testosterone due to dysfunction of either of the testes. Female hypogonadism refers to deficiency of estrogen or progesterone due to reduced activity of the ovaries. Hypogonadism is classified into two types: primary hypogonadism (testicular failure) and central hypogonadism (hypothalamic-pituitary axis dysfunction). Other major causes of hypogonadism include autoimmune disorder, genetic disorder, severe infections, and liver and kidney diseases. Generally, hormone and imaging tests are used to diagnose hypogonadism.

According to the Boston University School of Medicine, around 4 million to 5 million men in the U.S. were affected with hypogonadism in 2003. The incidence of hypogonadism in men aged between 40 years and 69 years in the country is around 481,000 new cases per year. According to the European Male Aging Study, the prevalence of late onset hypogonadism in men aged between 40 and 79 was 2.1% in 2016. Studies suggest that hypogonadism in adult men is often underdiagnosed and undertreated and only 5%. According to the Urology Care Foundation, hypogonadism is a chronic condition which would require lifelong treatment. The treatment for hypogonadism depends on the cause and concern about fertility and includes treatment such as hormone replacement therapy or assisted reproduction.

Men with heart disease, HIV, COPD, or renal disease have high prevalence of hypogonadism. Factors such as rising prevalence of type 2 diabetes and obesity further increase the incidence of hypogonadism. Growth of the global hypogonadism treatment market is attributed to rise in geriatric population, increase in infertility, and improved diagnosis. However, growing concerns about the potential side effects, availability of generic drugs, and preference for other natural hormonal boosters and supplements are likely to hamper the growth of the hypogonadism treatment market. Increasing awareness, awaiting approvals for new generation drugs in pipeline, and technological advancements present significant opportunities in the hypogonadism treatment market.

The primary treatment option for hypogonadism is hormone replacement therapy. Based on product type, the market has been classified into testosterone replacement therapy, estrogen therapy, and progesterone therapy. Testosterone replacement therapy is the fastest growing segment as hypogonadism is more prevalent in men. The segment is expected to hold major share of the global market during the forecast period.

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/hypogonadism-treatment-market.html

In terms of mode of administration, the hypogonadism treatment market has been broadly classified into transdermal patch, topical gel, buccal tablets, implantable pellet, intramuscular injections, and oral tablets. Transdermal patch followed by topical gels are anticipated to be the fastest growing segments as these provide steady route of administration and are easily modifiable over a short period of time. The oral and buccal tablets segments are anticipated to experience sluggish growth during the forecast period due to high side effects and liver diseases.

Based on the distribution channel they are segmented into hospital pharmacies, retail pharmacies and others. The major market share for the hypogonadism treatment market is for the retail pharmacies segment and is anticipated to rule the market during the forecast period as continuous long term treatment is required for the hypogonadism patient.

In terms of region, the global hypogonadism treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest market for hypogonadism treatment, accounting for more than half of the market share due to the factors such as increased adoption of newer highly advanced products, rising awareness about hormonal disorder including various treatment options available, and advancing health care infrastructure. However, Asia Pacific is anticipated to be the fastest growing market during the forecast period due to increasing urbanization and rise in the patient population.

Key players in the global hypogonadism treatment market are Bayer AG, Abbott Laboratories, Inc., Merck Serono, Sanofi, Merck & Co., Inc., Actavis, Inc., AbbVie Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Endo International plc, Ferring Holding S.A., and Laboratoires Genevrier.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Request Brochure of this report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=30392&source=atm

The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis

The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request For Discount On This Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=30392&source=atm

See the rest here:
Hypogonadism Treatment Market : Opportunities, Demand and Forecasts, 2017-2025 - Rapid News Network

Male hypogonadism is a condition in males wherein the testes depict a significantly reduced functioning level than normal. Reduction in rate of biosynthesis of the male sex hormones consequently results into male hypogonadism, which can vary in terms of severity among individuals. Partial or complete infertility are among major end-results entailing male hypogonadism, which in turn have created the need for effective treatment. XploreMR has published a new comprehensive research report titled, Male Hypogonadism Market: Global Industry Analysis (2012-2016) and Forecast (2017-2026). The report covers present market scenario as well as imparts future growth prospects of the male hypogonadism market for the period between 2017 and 2026. The report also engulfs key drivers, hindrances, opportunities and trends that are affecting expansion of the global male hypogonadism market. The report offers an overall picture of the global male hypogonadism market, in order to help businesses seeking opportunities for making investments in the market.

Get Sample Copy of this report at https://www.xploremr.com/connectus/sample/517

Structure of the Report

The report provides an exhaustive synopsis of the global male hypogonadism market, engulfing an executive summary that elucidates the core trends influencing the market expansion. This chapter also sheds light on impacts that the dynamics are likely to pose on growth of the market in the long run. The report also imparts figures appertaining to CAGRs from a historical and forecast point of view. An overview of the global male hypogonadism market follows the executive summary, and issues a clear picture of the markets scope to the report readers. The overview includes a concise market introduction succeeded by a formal definition of male hypogonadism. Chapters subsequent to the overview elaborates several dynamics including driving factors, limitations and prospects being observed in the market through the forecast period. Meanwhile these chapter also inundate detailed insights related to the bottom line of enterprises, global economy and fiscal stimulus.

Browse Full Report at https://www.xploremr.com/report/517/global-male-hypogonadism-market

Competition Landscape

This analytical research report on the global male hypogonadism market is a complete package, which includes intelligence on key participants underpinning the market expansion. In the last chapter of the report, which elucidates the competitive scenario of the market, strategies implemented by the market players, along with their product overview, company overview, key financials, key developments and SWOT analysis has been rendered exhaustively. In addition, region-wide spread of these market players, their future expansion plans, market shares, revenues, and mergers & acquisition activities between them have been described in detail in this concluding chapter of the report. An intensity map has been employed in the report to profile the market players situated across geographies.

Research Methodology

Credibility of the researched statistics and data is backed by the unique research methodology employed by the analysts at XMR, which ensures higher accuracy. XMRs research report on the global male hypogonadism market can assist its readers in gaining detailed insights on many different aspects governing the market around key regional segments included in the report. The report readers can further slate key strategies for tapping into vital revenue pockets and gaining benefits over the intensifying competition in the market. Information presented in the report has been scrutinized and monitored thoroughly by XMRs industry experts. Figures and numbers offered in the report have also been validated by the analysts in order to facilitate strategic decision making for the report readers.

Buy Full Report at https://www.xploremr.com/cart/517/SL

Read the original:
Male Hypogonadism Market To Increase at Steady Growth Rate - Fortune Enterpriser

Hypogonadism refers to diminished activity of reproductive organs producing little or no hormones. In males, hypogonadism refers to the decrease in either of the functions of the testes i.e. sperm production and testosterone production. It affects the men of all ages. While in females, hypogonadism refers to decreased activity of ovaries leading to reduction in the levels of estrogen and progesterone. Hypogonadism may lead to infertility, fatigue, muscle loss, depression, poor concentration and memory and reduced libido. Hypogonadism is classified into two categories namely, primary and secondary hypogonadism, based on the causative factors. Primary hypogonadism (hypergonadotropic hypogonadism) refers to abnormality in the gonads or testicles responsible for low androgen and estrogen levels. Whereas, in secondary hypogonadism (hypogonadotropic hypogonadism), the problem lies in the brain. The hypothalamus and pituitary gland in the brain, which control the gonads, arent working properly.

HypogonadismTreatment Market: Drivers and Restraints

Lack of sex hormones can lead to other complaints like increased risk of heart disease and osteoporosis, due to thinning of bones. This has led to the growth of hypogonadism treatment market. Moreover, the market has presence of patented brands with huge sales. Hypogonadism incidence will rise with increasing age and increasing incidence of obesity and rheumatoid arthritis. In addition, changing lifestyle habits associated with smoking and increasing stress levels also lead to reduced androgen and estrogen levels. These are some of the driving force for hypogonadism treatment market. However, the entry of generics would lead to sales erosion of the top brands in the market, thus restraining the hypogonadism treatment market to grow to certain extent.

HypogonadismTreatment Market: Segmentation

The hypogonadism treatment market can be segmented based on product type, distribution channel and geography.

Based on product type, hypogonadism treatment market can be segmented as follows:

Testosterone Replacement Therapy

Injection

Patch

Gel

Lozenge

Estrogen Therapy

Progesterone Therapy

Based on distribution channel, hypogonadism treatment market can be segmented as follows:

Hospitals including hospital pharmacies

Clinics

Get Sample Copy of this report at https://www.futuremarketinsights.com/reports/sample/rep-gb-1328?source=atm

Retail pharmacies

HypogonadismTreatment Market: Overview

The treatment modality for hypogonadism mainly incudes testosterone replacement through exogenous administration. However, for spermatogenesis, gonadotropins are preferred as testosterone is identified to be less effective. In females, estrogen and progesterone hormones are replaced by exogenous administration. Therefore, the market is analyzed based on hormonal replacement therapy as testosterone, gonadotropins, estrogen and progesterone. Pre-menopausal women can benefit from estrogen that comes in pill or patch form. Treatment for males and females is similar if the hypogonadism is due to a tumor on the pituitary gland. Treatment may include radiation, medication or surgery to shrink or remove the tumor.

HypogonadismTreatment Market: Region-wise Outlook

Region wise, the global hypogonadism treatment marketis classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America is the largest market for hypogonadism treatment with the presence of high prevalence of the disease. However, the industry will be experiencing higher demand from the developing regions such as Latin America, Asia-Pacific, Middle-East and Africa.

HypogonadismTreatment Market: Key Players

Some of the key players in the hypogonadism treatment market include Abbott Laboratories, Inc., Bayer AG, Eli Lilly and Company, Merck Serono, Merck & Co., Inc., Actavis, Inc. and Sanofi S.A.

The report covers exhaustive analysis on:

Market Segments

Market Dynamics

Market Size

Supply & Demand

Current Trends/Issues/Challenges

Competition & Companies involved

Technology

Value Chain

Regional analysis includes

Request to view TOC at https://www.futuremarketinsights.com/toc/rep-gb-1328?source=atm

North America (U.S., Canada)

Latin America (Mexico, Brazil)

Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)

Eastern Europe (Russia, Poland, Rest Of Eastern Europe)

Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)

Japan

Middle East and Africa (GCC, S. Africa, N. Africa, Rest Of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint.

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Customization for this report at https://www.futuremarketinsights.com/customization-available/rep-gb-1328?source=atm

Read the original post:
Hypogonadism Treatment Market Size, Scope, Manufacturing Cost Analysis, and Strategies - Herald Space

The male sex hormone androgens and anabolic steroids include di-hydro-testosterone, testosterone, and other agents. Androgen and anabolic steroid stimulate the development of male sex organs and male sexual characters such as growth of beard and deepening of voice. Various types of tissues grow due to stimulation of anabolic steroids, especially muscle and bone. Rise in red blood cells production is due to anabolic effects. Androgens and anabolic steroids are used for the treatment of breast cancer in women, impotence, hypogonadism in men, and replacement therapy for delayed puberty in adolescent boys. Androgens and anabolic steroids are also used for the treatment of various conditions with hormonal imbalance, weight loss, osteoporosis, and anemia.

Hypogonadism in men is caused by deficiency of androgen that adversely affects quality of life and multiple organ functions. Impotence is when men are unable to get erection. Impotence in men is primarily caused due to tiredness, lack of sleep, anxiety, and excessive intake of alcohol. Breast cancer in women is uncontrollable growth of the cells in the breast. These cells form tumor that can be felt as a lump or can often be seen on an X-ray. If these cells invade surrounding tissues, it is termed as malignant cancer.

Increase in geriatric population drives the androgens and anabolic steroids market, as older men are more prone to hypogonadism. Additionally, rise in obesity in men propels the global androgens and anabolic steroids market. The increasing poor health status especially in the developing countries is projected to fuel the growth of the market during the forecast period. Moreover, rise in government initiatives for better health care is attributed to the growth of the global androgens and anabolic steroids market. Increase in prevalence of hypogonadism among men is anticipated to augment the global androgens and anabolic steroids market during the forecast period. Rise in impotence among men due to obesity and tiredness is expected to boost demand for androgens and anabolic steroids during the forecast period.

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/androgens-anabolic-steroids-market.html

The global androgens and anabolic steroids market can be segmented based on dosage form, disease type, end-user, and region. In terms of dosage form, the market can be categorized into oral/buccal, intranasal sprays, implantable pellets, transdermal patches and gels, and intramuscular injections. Based on disease type, the global androgens and anabolic steroids market can be divided into breast cancer in women, impotence, hypogonadism in men, and delayed puberty in adolescent boys. In terms of end-user, the market can be classified into online pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market in 2016, owing to increased availability of drugs and hospitals being the first point of contact for treatment.

Geographically, the global androgens and anabolic steroids market can be segmented into Latin America, Asia Pacific, Europe, North America, and Middle East & Africa. North America held the largest market share in 2016, due to increased prevalence of breast cancer in women. According to many researches, breast cancer is one of the leading causes of death in the U.S. Europe held the second largest market share in 2016, due to increased prevalence of hypogonadism in men and delayed puberty in adolescent boys. The market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period owing to increased government initiatives to eradicate breast cancer. The global androgens and anabolic steroids market in Middle East & Africa is expected to be driven by increased prevalence of impotence, hypogonadism in men, and delayed puberty in adolescent boys. The market in Latin America is projected to witness strong growth during the forecast period due to increased government initiatives in the health care sector.

Key players in the global androgens and anabolic steroids market include Unimed Pharmaceuticals, Inc. and Valeant Pharmaceuticals North America LLC.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Request Brochure of this report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=39500&source=atm

The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis

The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request For Discount On This Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=39500&source=atm

The rest is here:
Androgens and Anabolic Steroids Market : Latest Innovations, Drivers and Industry Key Events 2018-2030 - RedfoxInfo

Latest Study on Industrial Growth of Global Hypogonadism Drug Market. A detailed study accumulated to offer Latest insights about acute features of the Hypogonadism Drug market. The report contains different market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary and SWOT analysis. Some are the key players taken under coverage for this study are AbbVie Inc., ALLERGAN, AstraZeneca, Bayer AG., Eli Lilly and Company, Clarus Therapeutics, Endo Pharmaceuticals Inc, Merck & Co., Inc., Ferring B.V., Richter Gedeon Vegyeszeti Gyar Nyrt, IBSA Institut Biochimque SA, Laboratoires Genevrier., Teva Pharmaceutical Industries Ltd, Lipocine Inc., Antares Pharma, Pfizer Inc., Aytu BioScience, Inc., Diurnal, HYUNDAIPHARM. Co Ltd., Perrigo Company plc, Bio-Techne.

Global hypogonadism drug market is rising gradually with a substantial CAGR in the forecast period of 2019-2026. Growing number hypogonadism population and robust product pipeline are the key drivers for market growth.

Click to get Global Hypogonadism Drug Market Research Sample PDF Copy Here @: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hypogonadism-drug-market

Drivers and Restraints of the Hypogonadism Drug Industry

Market Drivers

Increase in prevalence rate of hypogonadism worldwide acts as a driver for the market

Increase in the rate of research and development initiatives is driving the market

Rising awareness about hypogonadism therapy and technological advancement is driving the market growth

Ongoing clinical trials is being carried out by many pharmaceuticals companies which acts as a driver for the market

Market Restraints

Effective treatment is either unavailable or unaffordable

Patent expiry of major drugs and introduction of generic drugs of branded version is expected to restrain the growth if the market

Global Hypogonadism Drug Market Overview:

If you are involved in the Hypogonadism Drug industry or intend to be, then this study will provide you comprehensive outlook. Its vital you keep your market knowledge up to date segmented by Type, Application, Channel (Direct Sales, Distributor). If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization according to your requirement.

With the clear understanding of customer requirement, one method or combination of many methods have been used to construct the most excellent Hypogonadism Drug market research report. Market parameters covered in Hypogonadism Drug report can be listed as market definition, currency and pricing, market segmentation, market overview, premium insights, key insights and company profile of the key market players. The verified, best and advanced methods and tools such as SWOT analysis and Porters Five Forces Analysis are used carefully while generating this Hypogonadism Drug market research report. The Hypogonadism Drug report is highly beneficial in planning of production, product launches, costing, inventory, purchasing and marketing strategies.

View Detailed Table of Content @ https://www.databridgemarketresearch.com/toc/?dbmr=global-hypogonadism-drug-market

The titled segments and sub-section of the market are illuminated below:

By Type: Hypergonadotropic Hypogonadism and Hypogonadotropic Hypogonadism

By Therapy Type: Testosterone Replacement Therapy and Steroid Replacement Therapy

By Mechanism of Action Type: Steroidal Androgens &Gonadotropins

By Route of Administration: Oral, Injectable, Tropical

By End- Users: Hospitals, Homecare, Specialty Clinics

Region Included are: United States, Europe, China, Japan, Southeast Asia, India & Central & South America

Top Players in the Market are: AbbVie Inc., ALLERGAN, AstraZeneca, Bayer AG., Eli Lilly and Company, Clarus Therapeutics, Endo Pharmaceuticals Inc, Merck & Co., Inc., Ferring B.V., Richter Gedeon Vegyeszeti Gyar Nyrt, IBSA Institut Biochimque SA, Laboratoires Genevrier., Teva Pharmaceutical Industries Ltd, Lipocine Inc., Antares Pharma, Pfizer Inc., Aytu BioScience, Inc., Diurnal, HYUNDAIPHARM. Co Ltd., Perrigo Company plc, Bio-Techne

To stay ahead of the competition, a thorough idea about the competitive landscape, their product range, their strategies, and future prospects are very valuable. This Hypogonadism Drug market research report involves a key data and information about the market, emerging trends, product usage, motivating factors for customers and competitors, restraints, brand positioning, and customer behaviour, which is of utmost importance when it comes to achieving a success in the competitive marketplace. This market research report is all-inclusive and encompasses various parameters of market. Hypogonadism Drug market research report comprises of the major market insights that takes your business to the next level of success and growth.

Important Features that are under offering & key highlights of the report:

Detailed overview of Hypogonadism Drug market

Changing market dynamics of the industry

In-depth market segmentation by Type, Application etc.

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape of Hypogonadism Drug market

Strategies of key players and product offerings

Potential and niche segments/regions exhibiting promising growth

A neutral perspective towards Hypogonadism Drug market performance

Must-have information for market players to sustain and enhance their market footprint

Buy Full Copy Global Hypogonadism Drug Report @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-hypogonadism-drug-market

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

Continued here:
Hypogonadism Drug Market Shows Strong Growth| Endo Pharmaceuticals, Clarus Therapeutics, Perrigo - Business Intelligence

Northland Securities set a $10.00 price target on Aytu Bioscience (NASDAQ:AYTU) in a research note released on Friday morning, TipRanks reports. The firm currently has a buy rating on the stock.

Several other analysts have also issued reports on AYTU. ValuEngine upgraded shares of Aytu Bioscience from a hold rating to a buy rating in a research report on Thursday, August 1st. Zacks Investment Research lowered shares of Aytu Bioscience from a buy rating to a hold rating in a research report on Friday, August 2nd.

NASDAQ AYTU opened at $1.43 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.10 and a quick ratio of 3.76. The firm has a market capitalization of $23.20 million, a price-to-earnings ratio of -0.05 and a beta of 4.65. The companys fifty day moving average is $1.41 and its two-hundred day moving average is $1.69. Aytu Bioscience has a 52-week low of $0.68 and a 52-week high of $4.80.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Searle & CO. grew its position in Aytu Bioscience by 1,241.6% in the 2nd quarter. Searle & CO. now owns 201,247 shares of the companys stock worth $380,000 after purchasing an additional 186,247 shares during the last quarter. BlackRock Inc. acquired a new stake in Aytu Bioscience in the 2nd quarter worth $36,000. Finally, Bank of New York Mellon Corp acquired a new stake in Aytu Bioscience in the 2nd quarter worth $75,000. Institutional investors own 19.20% of the companys stock.

About Aytu Bioscience

Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia.

Featured Article: Why is the LIBOR significant?

Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

More here:
Northland Securities Analysts Give Aytu Bioscience (NASDAQ:AYTU) a $10.00 Price Target - TechNewsObserver

Testosterone Replacement Therapy Global Market 2019-2024 covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market. Global Testosterone Replacement Therapy Market report provides strategists, marketers and senior management with the critical information they need to assess the global Testosterone Replacement Therapy sector.

The market size section gives the Testosterone Replacement Therapy market revenues, covering both the historic growth of the market and forecasting the future.

AccessGlobal Testosterone Replacement Therapy Market Research ReportDetails at: athttps://www.pioneerreports.com/report/301292

About Testosterone Replacement Therapy Industry

Testosterone deficiency, also referred to as hypogonadism, is a common problem among men aged between 40 and 79 years, with some studies stating that nearly 30% of all men worldwide are affected by hypogonadism. As the incidence of testosterone deficiency increases, it is expected that the demand for TRT will also show a simultaneous increase.

The global average price of testosterone replacement therapy is in the decreasing trend, from 45.4 USD/Unit in 2012 to 34.9 USD/Unit in 2016. With the situation of global economy, prices will be in decreasing trend in the following five years.

The classification of testosterone replacement therapy includes gels, injections, patches and other types, and the proportion of gels in 2016 is about 72%.

Testosterone replacement therapy is widely sold in hospitals, clinics and other field. The most proportion of testosterone replacement therapy is sold in clinics, and the consumption proportion is about 43%.

North America region is the largest supplier of testosterone replacement therapy, with a production market share nearly 86% in 2016. Europe is the second largest supplier of Testosterone Replacement Therapy, enjoying production market share nearly 9.9% in 2016.

North America is the largest consumption place, with a consumption market share nearly 83% in 2016. Following North America, Europe is the second largest consumption place with the consumption market share of 12%.

Market competition is intense. AbbVie, Endo International, Eli Lilly, Pfizer, Actavis (Allergan)Bayer, etc. are the leaders of the industry. The top five players together held about 80% of the market in the same year and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.

The worldwide market for Testosterone Replacement Therapy is expected to grow at a CAGR of roughly -4.2% over the next five years, will reach 1410 million US$ in 2024, from 1820 million US$ in 2019, according to a new GIR (Global Info Research) study.This report focuses on the Testosterone Replacement Therapy in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The overviews, SWOT analysis and strategies of each vendor in the Testosterone Replacement Therapy market provide understanding about the market forces and how those can be exploited to create future opportunities.

Key Players in this Testosterone Replacement Therapy market are:

Request for Sample Copy of this Testosterone Replacement Therapy Market Report athttps://www.pioneerreports.com/request-sample/301292

Production Analysis:SWOT analysis of major key players ofTestosterone Replacement Therapy industry based on a Strengths, Weaknesses, companys internal & external environments. , Opportunities and Threats. . It also includesProduction, Revenue, and average product price and market shares of key players. Those data are further drilled down with Manufacturing Base Distribution, Production Area and Product Type. Major points like Competitive Situation and Trends, Concentration Rate Mergers & Acquisitions, Expansion which are vital information to grow/establish a business is also provided.

Application of Testosterone Replacement Therapy Market are:

Product Segment Analysis of the Testosterone Replacement Therapy Market is:

Look into Table of Content of Testosterone Replacement Therapy Market Report at https://www.pioneerreports.com/TOC/301292

Regions Covered in Testosterone Replacement Therapy Market are:-

Inquire for further detailed information of Testosterone Replacement Therapy Market Report at:https://www.pioneerreports.com/pre-order/301292

Why should you buy Testosterone Replacement Therapy Market Report?

In this study, the years considered to estimate the market size ofTestosterone Replacement Therapy Market are as follows:-

Single User Licence Price: USD 3480

No Of Pages in Testosterone Replacement Therapy Market Report: 120

Purchase of Testosterone Replacement Therapy Market Report at:https://www.pioneerreports.com/checkout/301292

More:
Global Testosterone Replacement Therapy Market Economic Trends, Industry Development, Challenges, Forecast and Strategies To 2024 - Manufacturing News...

Hypogonadism is separated into two types: primary hypogonadism (resulting from dysfunction of the testis or ovary) or central hypogonadism (resulting from pituitary or hypothalamic dysfunction that leads to loss of lutenizing horomne [LH] and follicle-stimulating hormone [FSH]).

Causes of hypogondaism include genetic, menopausual, autoimmune, viral, radiation, and chemotherapeutic agents. Central hypogonadism is often due to pituitary adenomas. Through compression of the gland, these tumors can cause destruction of pituitary tissue or interference with gonadotropin-releasing hormone (GnRH) input from the hypothalamus. Gonadotropin dysfunction is the second most common hormonal disorder from compression of the pituitary gland from a pituitary adenoma after GH suppression. Hypothalamic disorders such as tumors and hypothalamic amenorrhea, as well as exposure to radiation, can lead to hypogonadism. Fasting, weight loss, anorexia nervosa, bulimia, exercise, or stressful conditions result in defects in pulsatile GnRH secretion ("hypothalamic amenorrhea"). Elevated prolactin levels can also suppress GnRH pulses and lead to hypothalamic hypogonadism. Diagonisis requires measurement of LH, FSH, and testosterone or estrogen, with reference to age-adjusted normal values.

Hypogonadism in prepubertal children causes no symptoms, whereas in adolescents, it leads to delayed or absent sexual development.

In adult women, hypogonadism causes:

Prolonged periods of hypogonadism can cause osteoporosis.

In men, hypogonadism leads to:

Most cases of hypogonadism can be successfully treated. Treatment of hypogonadism in men and premenopausal women is effectively accomplished by replacement hormonal therapy. Fertility can be restored by administration of human chorionic gonadotropin, which acts like LH, often in combination with FSH, or by the pulsatile administration of GnRH. Treatment for hypogonadism resulting from a pituitary tumor includes surgery to remove the tumor.

View post:
Hypogonadism | California Center for Pituitary Disorders

Hypogonadism, in men, decreased testicular function that results in testosterone deficiency and infertility.

Hypogonadism is caused by hypothalamic, pituitary, and testicular diseases. Hypothalamic and pituitary diseases that may cause decreased testicular function include tumours and cysts of the hypothalamus, nonsecreting and prolactin-secreting pituitary tumours, trauma, hemochromatosis (excess iron storage), infections, and nonendocrine disorders, such as chronic illness and malnutrition. The primary testicular disorders that result in hypogonadism in postpubertal men include Klinefelter syndrome and related chromosomal disorders, although these disorders usually manifest at the time of puberty.

Other causes of hypogonadism in men include testicular inflammation (orchitis) caused by mumps; exposure to gonadal toxins, including alcohol, marijuana, and several anticancer drugs (e.g., cyclophosphamide, procarbazine, and platinum); and radiation with X-rays. Many of the disorders that cause delayed puberty are sufficiently mild that affected men do not seek care until well into adult life. This particularly applies to those disorders that decrease spermatogenesis and therefore fertility but spare Leydig cell function.

The clinical manifestations of hypogonadism in adult men include decreased libido, erectile dysfunction (inability to have or maintain an erection or to ejaculate), slowing of facial and pubic hair growth and thinning of hair in those regions, drying and thinning of the skin, weakness and loss of muscle mass, hot flashes, breast enlargement, infertility, small testes, and osteoporosis (bone thinning). The evaluation of men suspected to have hypogonadism should include measurements of serum testosterone, luteinizing hormone, follicle-stimulating hormone, and prolactin, in addition to the analysis of semen. Men with hypogonadism who have decreased or normal serum gonadotropin concentrations are said to have hypogonadotropic hypogonadism and may need to be evaluated for hypothalamic or pituitary disease with computerized axial tomography or magnetic resonance imaging (MRI) of the head. Men with hypogonadism who have increased serum gonadotropin concentrations are said to have hypergonadotropic hypogonadism, and their evaluation should be focused on the causes of testicular disease, including chromosomal disorders.

Men with hypogonadism caused by a hypothalamic disorder, pituitary disorder, or testicular disorder, such as Klinefelter syndrome, are treated with testosterone, which may be injected, applied transdermally (i.e., as a skin patch), or taken orally. Testosterone treatment reverses many of the symptoms and signs of hypogonadism but will not increase sperm count. Sperm count cannot be increased in men with testicular disease, although it is sometimes possible to increase sperm count in men with hypothalamic or pituitary disease by prolonged administration of gonadotropin-releasing hormone or gonadotropins. In men with testicular disease, viable sperm can sometimes be obtained by aspiration from the testes for in vitro fertilization.

Read the original here:
hypogonadism | Definition, Causes, Symptoms, & Treatment ...

Medically reviewed on Oct 1, 2018

Male hypogonadism is a condition in which the body doesn't produce enough testosterone the hormone that plays a key role in masculine growth and development during puberty or has an impaired ability to produce sperm or both.

You may be born with male hypogonadism, or it can develop later in life, often from injury or infection. The effects and what you can do about them depend on the cause and at what point in your life male hypogonadism occurs. Some types of male hypogonadism can be treated with testosterone replacement therapy.

Hypogonadism can begin during fetal development, before puberty or during adulthood. Signs and symptoms depend on when the condition develops.

If the body doesn't produce enough testosterone during fetal development, the result may be impaired growth of the external sex organs. Depending on when hypogonadism develops and how much testosterone is present, a child who is genetically male may be born with:

Male hypogonadism may delay puberty or cause incomplete or lack of normal development. It can cause:

In adult males, hypogonadism may alter certain masculine physical characteristics and impair normal reproductive function. Signs and symptoms may include:

Hypogonadism can also cause mental and emotional changes. As testosterone decreases, some men may experience symptoms similar to those of menopause in women. These may include:

See a doctor if you have any symptoms of male hypogonadism. Establishing the cause of hypogonadism is an important first step to getting appropriate treatment.

The male reproductive system makes, stores and moves sperm. Testicles produce sperm. Fluid from the seminal vesicles and prostate gland combine with sperm to make semen. The penis ejaculates semen during sexual intercourse.

Male hypogonadism means the testicles don't produce enough of the male sex hormone testosterone. There are two basic types of hypogonadism:

Either type of hypogonadism may be caused by an inherited (congenital) trait or something that happens later in life (acquired), such as an injury or an infection. At times, primary and secondary hypogonadism can occur together.

Common causes of primary hypogonadism include:

In secondary hypogonadism, the testicles are normal but function improperly due to a problem with the pituitary or hypothalamus. A number of conditions can cause secondary hypogonadism, including:

The rate at which testosterone declines varies greatly among men. As many as 30 percent of men older than 75 have a testosterone level that's below the normal range of testosterone in young men. Whether treatment is necessary remains a matter of debate.

The pituitary gland and the hypothalamus are situated within the brain and control hormone production.

Risk factors for hypogonadism include:

Hypogonadism can be inherited. If any of these risk factors are in your family health history, tell your doctor.

The complications of untreated hypogonadism differ depending on what age it first develops during fetal development, puberty or adulthood.

A baby may be born with:

Pubertal development can be delayed or incomplete, resulting in:

Complications may include:

Your doctor will conduct a physical exam during which he or she will note whether your sexual development, such as your pubic hair, muscle mass and size of your testes, is consistent with your age. Your doctor may test your blood level of testosterone if you have any of the signs or symptoms of hypogonadism.

Early detection in boys can help prevent problems from delayed puberty. Early diagnosis and treatment in men offer better protection against osteoporosis and other related conditions.

Doctors base a diagnosis of hypogonadism on symptoms and results of blood tests that measure testosterone levels. Because testosterone levels vary and are generally highest in the morning, blood testing is usually done early in the day, before 10 a.m.

If tests confirm you have low testosterone, further testing can determine if a testicular disorder or a pituitary abnormality is the cause. Based on specific signs and symptoms, additional studies can pinpoint the cause. These studies may include:

Testosterone testing also plays an important role in managing hypogonadism. This helps your doctor determine the right dosage of medication, both initially and over time.

Treatment for male hypogonadism depends on the cause and whether you're concerned about fertility.

Hormone replacement. For hypogonadism caused by testicular failure, doctors use male hormone replacement therapy (testosterone replacement therapy, or TRT). TRT can restore muscle strength and prevent bone loss. In addition, men receiving TRT may experience an increase in energy, sex drive, erectile function and sense of well-being.

If a pituitary problem is the cause, pituitary hormones may stimulate sperm production and restore fertility. Testosterone replacement therapy can be used if fertility isn't an issue. A pituitary tumor may require surgical removal, medication, radiation or the replacement of other hormones.

In boys, testosterone replacement therapy (TRT) can stimulate puberty and the development of secondary sex characteristics, such as increased muscle mass, beard and pubic hair growth, and growth of the penis. Pituitary hormones may be used to stimulate testicle growth. An initial low dose of testosterone with gradual increases may help to avoid adverse effects and more closely mimic the slow increase in testosterone that occurs during puberty.

Several testosterone delivery methods exist. Choosing a specific therapy depends on your preference of a particular delivery system, the side effects and the cost. Methods include:

Injection. Testosterone injections (testosterone cypionate, testosterone enanthate) are safe and effective. Injections are given in a muscle. Your symptoms might fluctuate between doses depending on the frequency of injections.

You or a family member can learn to give TRT injections at home. If you're uncomfortable giving yourself injections, a nurse or doctor can give the injections.

Testosterone undecanoate (Aveed), an injection recently approved by the Food and Drug Administration, is injected less frequently but must be administered by a health care provider and can have serious side effects.

Gel. There are several gel preparations available with different ways of applying them. Depending on the brand, you either rub testosterone gel into your skin on your upper arm or shoulder (AndroGel, Testim, Vogelxo), apply with an applicator under each armpit (Axiron) or pump on your front and inner thigh (Fortesta).

As the gel dries, your body absorbs testosterone through your skin. Gel application of testosterone replacement therapy appears to cause fewer skin reactions than patches do. Don't shower or bathe for several hours after a gel application, to be sure it gets absorbed.

A potential side effect of the gel is the possibility of transferring the medication to another person. Avoid skin-to-skin contact until the gel is completely dry or cover the area after an application.

Oral testosterone isn't recommended for long-term hormone replacement because it might cause liver problems.

Testosterone therapy carries various risks, including contributing to sleep apnea, stimulating noncancerous growth of the prostate, enlarging breasts, limiting sperm production, stimulating growth of existing prostate cancer and blood clots forming in the veins. Recent research also suggests testosterone therapy might increase your risk of a heart attack.

Reduce stress. Talk with your doctor about how you can reduce the anxiety and stress that often accompany these conditions. Many men benefit from psychological or family counseling.

Support groups can help people with hypogonadism and related conditions cope with similar situations and challenges. Helping your family understand the diagnosis of hypogonadism also is important.

Although you're likely to start by seeing your family doctor or general practitioner, you may need to consult a doctor who specializes in the hormone-producing glands (endocrinologist). If your primary care doctor suspects you have male hypogonadism, he or she may refer you to an endocrinologist. Or, you can ask for a referral.

The following information will help you prepare for your appointment, and understand what to expect from your doctor.

Preparing a list of questions for your doctor will help you make the most of your time together. For male hypogonadism, some basic questions to ask your doctor include:

Don't hesitate to ask other questions you have.

Examples of questions your doctor may ask, include:

1998-2019 Mayo Foundation for Medical Education and Research (MFMER). All rights reserved. Terms of use

Follow this link:
Male hypogonadism Disease Reference Guide - Drugs.com